Advertisement

Topics

Latest "Aplidin - Dexamethasone in Relapsed/Refractory Myeloma" News Stories

05:01 EDT 22nd March 2019 | BioPortfolio

Here are the most relevant search results for "Aplidin - Dexamethasone in Relapsed/Refractory Myeloma" found in our extensive news archives from over 250 global news sources.

More Information about Aplidin - Dexamethasone in Relapsed/Refractory Myeloma on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Aplidin - Dexamethasone in Relapsed/Refractory Myeloma for you to read. Along with our medical data and news we also list Aplidin - Dexamethasone in Relapsed/Refractory Myeloma Clinical Trials, which are updated daily. BioPortfolio also has a large database of Aplidin - Dexamethasone in Relapsed/Refractory Myeloma Companies for you to search.

Showing "Aplidin Dexamethasone Relapsed Refractory Myeloma" News Articles 1–25 of 1,600+

Friday 22nd March 2019

I-Mab Starts Greater China Trials of CD38 Antibody for Myeloma

I-Mab Biopharma, a Shanghai company focused on immuno-oncology and autoimmune diseases, dosed the first patient in a Phase II Taiwan trial of a CD38 antibody in patients with relapsed or refractory multiple myeloma. In 2017, I-Mab acquired greater China rights to TJ202/MOR202 from MorphoSys AG in a $120 million deal. The multi-center trial, which will also include mainland China sites, is designed...


Thursday 21st March 2019

Multiple links between stress and breast cancer progression

In mid-February, a study led by Chinese researchers established that the stress hormone epinephrine sets off a cascade of biochemical reactions that favour breast cancer growth and spread. Their work was published in The Journal of Clinical Investigation. The researchers first demonstrated the effects of chronic stress on cancer stem cell growth, in a twist on previous research that did not speci...

IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs

Attained multiple milestones in DECIDE1/2 clinical program in advanced ovarian cancer Achieved initial positive data from phase 2 clinical trial in DLBCL with Merck Initiated a phase 2 basket trial across five indications under a collaboration with Merck Listed on Nasdaq and changed Corpora...


GlaxoSmithKline targets regulatory filings by year end for anti-BCMA drug GSK2857916 in multiple myeloma https://www.firstwordpharma.com/node/1630817  $GSK

GlaxoSmithKline targets regulatory filings by year end for anti-BCMA drug GSK2857916 in multiple myeloma https://www.firstwordpharma.com/node/1630817  $GSK

The AM Charity Fund Introduces Their First Theater Show “The Evolution of Dance” to Raise Money for LLS Says 360Wise Media

Since the beginning of time, music and dance has influenced art and culture around the world. To celebrate this, Twin Cities Arthur Murray Dance Centers will sponsor AM Charity Fund’s first Theater Show, the Evolution of Dance, Saturday, March 30th at the Woman’s Club of Minneapolis. MINNEAPOLIS (PRWEB) March 21, 2019 Arthur Murray dancers, both amateurs and professionals will perform dances ...

Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors

– Shawn Cline Tomasello and Stephen T. Wills bring extensive experience in building successful commercial-stage life sciences companies – Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced the nominations of Shawn Cline Tomasello and Stephen T. Wills to its board of directors. These nominatio...

Human medicines European public assessment report (EPAR): Bortezomib Hospira, bortezomib, Multiple Myeloma, Date of authorisation: 22/07/2016, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Bortezomib Hospira, bortezomib, Multiple Myeloma, Date of authorisation: 22/07/2016, Revision: 6, Status: Authorised

AB2 Bio Announces Readiness for Recruitment in Pivotal Phase 3 Trial of Tadekinig Alfa, a Novel Human Recombinant Interleukin-18 Binding Protein, in Children with Genetic Diagnosis of NLRC4-MAS Mutation or XIAP Deficiency, with Amended Design in the U.S.

LAUSANNE, Switzerland, March 21, 2019 / B3C newswire / -- AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company, specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, announced today that a single-arm open label design with a randomized withdrawal phase for its ongoing pivotal Phase 3 trial under an Investigational New Drug (IND) App...

Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody

SUZHOU, China, March 21, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the first patient has been successfully dosed in a Phase IIa clinical study of IBI306, a recombinant fully human anti-proprotein convertase substilisin/kexin type 9 (anti-PCSK...

Heidelberg Pharma AG announces financial figures for fiscal year 2018 and provides business update

DGAP-News: Heidelberg Pharma AG / Key word(s): Annual Results 21.03.2019 / 06:59 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma announces financial figures for fiscal year 2018 and provides business update - Key milestones reached for GMP manufacturing of HDP-101 - Preparation of the clinical trial with HDP-101 advanced - Licensi...

Clinical Trials With Venetoclax on Hold Because of Deaths

The FDA issued a partial hold on all ongoing clinical trials evaluating venetoclax in multiple myeloma because of an excessive number of deaths seen in the BELLINI study. News Alerts

Clinical Trials of Venetoclax in Myeloma Stopped Due to Deaths

The FDA issued a partial hold on all ongoing clinical trials evaluating venetoclax in multiple myeloma because of an excessive number of deaths seen in the BELLINI study. News Alerts

Wednesday 20th March 2019

FDA puts multiple myeloma trial on hold after patient deaths http://bit.ly/2U5oA6V  #cancer #oncology #clinicaltrials

FDA puts multiple myeloma trial on hold after patient deaths http://bit.ly/2U5oA6V  #cancer #oncology #clinicaltrials

AbbVie, Roche’s Venclexta stumbles amid patient deaths in multiple myeloma trial

AbbVie said Tuesday that the FDA had placed a partial clinical hold on all Venclexta studies in

Human medicines European public assessment report (EPAR): Bortezomib Sun, bortezomib, Multiple Myeloma, Date of authorisation: 22/07/2016, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Bortezomib Sun, bortezomib, Multiple Myeloma, Date of authorisation: 22/07/2016, Revision: 6, Status: Authorised

Vaccine Boosts OS in Late-Stage, Relapsed Ovarian Cancer

(MedPage Today) -- Survival at 2 years was 72.4% versus 40.9% with chemotherapy alone

An Unexpected Halt in Multiple Myeloma for Venetoclax

  Venetoclax (ABT-199) is an unusual drug. But now there’s some unusually bad (and unexpected) news about it. That’s the structure at right, and medicinal chemists will understand immediately why it’s a bit of an outlier. With a molecular weight of 868, that structure just keeps on going, with a somefeatures that you don’t usually see,

FDA issues partial hold on studies of AbbVie, Roche drug in multiple myeloma

A higher proportion of deaths were observed in the treatment arm versus control group of a study testing Venclexta in the blood cancer.

Recommendations Issued for HSCT in Multiple Myeloma

WEDNESDAY, March 20, 2019 -- A consensus statement for the use of hematopoietic stem cell transplantation (HSCT) in the treatment of multiple myeloma (MM) has been developed by Mayo Clinic physicians; the recommendations were published in the March...

Question marks over AbbVie/Roche's venetoclax after safety scare

AbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a higher proportion of deaths was observed in patients receiving it than in a trial’s control arm. AbbVie, which is developing th...

FDA puts multiple myeloma trial on hold after patient deaths http://bit.ly/2U5oA6V  #cancer #oncology #clinicaltrialspic.twitter.com/hX8qJTR2ei

FDA puts multiple myeloma trial on hold after patient deaths http://bit.ly/2U5oA6V  #cancer #oncology #clinicaltrials pic.twitter.com/hX8qJTR2ei

FDA puts multiple myeloma trial on hold after patient deaths

The FDA has placed a partial clinical hold on studies of multiple myeloma treatment Venclexta/Venclyxto (venetoclax) following a number of patient deaths in a late stage study. AbbVie who are developing the drug with Roche said the hold should not affect any of the improved indications such as in chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). The FDA made the decision after...

AbbVie-Roche’s multiple myeloma trials halted by FDA

AbbVie has announced the US Food and Drug Administration (FDA) has placed a partial clinical hold on all clinical trials...Read More... The post AbbVie-Roche’s multiple myeloma trials halted by FDA appeared first on Pharmaceutical Technology.

I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

SHANGHAI, March 20, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, and German biopharma company MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR), today announced that the first pat...

Tuesday 19th March 2019

piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks